Pierre Legrain leaves his post as CTO of Hybrigenics to lead the biology department at the French Atomic Energy Commission.
Thomas Ingolia heads to Myriad Proteomics, where he will take the reins as president and CEO. Ingolia worked at Curis and Microbia after spending 13 years at Eli Lilly.
Zyomyx welcomes some new faces. Thomas McNaughton, formerly of Aclara Biosciences, joins as vice president of intellectual property. And John Lewis, fresh from BD Biosciences Clontech, takes over as VP for sales and marketing. Meanwhile, Hirday Bhathal will step down from his role as VP of corporate development.
Gregory Gorman is appointed director of the Bioanalytical Sciences Department, a new division in the drug development group at the Southern Research Institute. Gorman, who joined the institute four years ago, has already started a proteomics laboratory there.
OmniViz announces the promotion of Jeffrey Saffer to the post of president. Saffer, who worked at Battelle before joining OmniViz in 2000, will continue his former role of CTO as well for the Massachusetts-based informatics firm.
Canada’s National Research Council reorganized. As a result, Michael Raymont becomes VP of technology and industry support, and Peter Hackett is in charge of life sciences and information technology as well as being VP of research and technology development.
Large Scale Biology announces a restructuring, and also the departure of David McGee, who co-founded the company in 1987. McGee plans to go into consulting for biotech.
Proteome Systems names William Emhiser as president of North American operations, heading up the Boston-based division.
Todd Edwards joins Protedyne as a field technical specialist for the Western US. He comes from a postdoc position at Lawrence Livermore National Lab.
Rajinder Kaul, scientific coordinator at the University of Washington Genome Center, is the primary award-winner for a $250,000 grant from Applied Biosystems. Kaul’s research involves direct detection of DNA sequence variation in long patterns. Other winners included Dawn Richardson, Stephen Sawcer, and Sue Rutherford.
Tom Yager joins ChondroGene as director of product development and quality assurance. Yager worked most recently at pharmacogenomics firm Visible Genetics.